Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 17:2020:8659802.
doi: 10.1155/2020/8659802. eCollection 2020.

Minocycline in Treating Glioblastoma Multiforme: Far beyond a Conventional Antibiotic

Affiliations
Review

Minocycline in Treating Glioblastoma Multiforme: Far beyond a Conventional Antibiotic

Amir R Afshari et al. J Oncol. .

Abstract

One of the most lethal forms of CNS pathologies is glioblastoma multiforme (GBM) that represents high invasiveness, uncontrolled proliferation, and angiogenic features. Its invasiveness is responsible for the high recurrence even after maximal surgical interventions. Minocycline is a semisynthetic analog of tetracyclines with potential anti-inflammatory and anticancer effects, distinct from its antimicrobial activity. In this review, we highlight the importance and the cytotoxic mechanisms of minocycline on GBM pathophysiology. Considering the role of certain enzymes in autophagy, apoptosis, tumor cell invasion, and metastatic ability, the possible use of tetracyclines for cancer therapy should be investigated, especially GBM. The present study is, therefore, going to cover the main topics in minocycline pharmacology to date, encouraging its consideration as a new treatment approach for cancer and GBM.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
The proposed mechanisms of action of minocycline against GBM.

Similar articles

Cited by

References

    1. Blaskovich M. A., Elliott A. G., Kavanagh A. M., Ramu S., Cooper M. A. In vitro antimicrobial activity of acne drugs against skin-associated bacteria. Scientific Reports. 2019;9(1):1–8. doi: 10.1038/s41598-019-50746-4. - DOI - PMC - PubMed
    1. di Cerbo A., Pezzuto F., Guidetti G., Canello S., Corsi L. Tetracyclines: insights and updates of their use in human and animal pathology and their potential toxicity. The Open Biochemistry Journal. 2019;13(1) doi: 10.2174/1874091x01913010001. - DOI
    1. Panahi Y, Sahebkar A., Naderi Y., Barreto G. E. Neuroprotective effects of minocycline on focal cerebral ischemia injury: a systematic review. Neural Regeneration Research. 2020;15(5):773–782. doi: 10.4103/1673-5374.268898. - DOI - PMC - PubMed
    1. Cankaya S., Cankaya B., Kilic U., Kilic E., Yulug B. The therapeutic role of minocycline in Parkinson’s disease. Drugs in Context. 2019;8 doi: 10.7573/dic.212553. - DOI - PMC - PubMed
    1. Noble W., Garwood C. J., Hanger D. P. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding. Prion. 2009;3(2):78–83. doi: 10.4161/pri.3.2.8820. - DOI - PMC - PubMed

LinkOut - more resources